Systemic Immune-Inflammation Index and Mortality in Testicular Cancer: A Systematic Review and Meta-Analysis

• Autores: Salazar-Valdivia, Farley E., Valdez-Cornejo, Valeria A., Ulloque-Badaracco, Juan R., Hernandez-Bustamante, Enrique A., Alarcón-Braga, Esteban A., Mosquera-Rojas, Melany D., Garrido-Matta, Diana P., Herrera-Añazco, Percy, Benites-Zapata, Vicente A., Hernandez, Adrian V.
• Formato: artículo
• Fecha de Publicación: 2023
• Institución: Universidad Peruana de Ciencias Aplicadas
• Repositorio: UPC-Institucional
• Lenguaje: inglés
• OAI Identifier: oai:repositorioacademico.upc.edu.pe:10757/668178
• Enlace del recurso: http://hdl.handle.net/10757/668178
• Nivel de acceso: acceso abierto
• Materia: meta-analysis; overall survival; progression free survival; systemic immune-inflammation index; testicular cancer; Urologic cancer; Testicular cancer; Overall survival (OS); Progression-free survival (PFS); Observational studies; Hazard ratio (HR); Newcastle–Ottawa Scale (NOS); Bias; Primary studies

The systemic immune-inflammation index (SIII) is a marker studied in multiple types of urologic cancer. This systematic review evaluates the association between SIII values with overall survival (OS) and progression-free survival (PFS) in testicular cancer. We searched observational studies in five databases. The quantitative synthesis was performed using a random-effects model. The risk of bias was assessed using the Newcastle–Ottawa Scale (NOS). The only measure of the effect was the hazard ratio (HR). A sensitivity analysis was performed according to the risk of bias in the studies. There were 833 participants in a total of 6 cohorts. We found that high SIII values were associated with worse OS (HR = 3.28; 95% CI 1.3–8.9; p < 0.001; I2 = 78) and PFS (HR = 3.9; 95% CI 2.53–6.02; p < 0.001; I2 = 0). No indication of small study effects was found in the association between SIII values and OS (p = 0.5301). High SIII values were associated with worse OS and PFS. However, further primary studies are suggested to enhance the effect of this marker in different outcomes of testicular cancer patients.